@article{59b912aa9b0a483da76320eea60b93bc,
title = "Pupillary light reaction in preclinical Alzheimer's disease subjects compared with normal ageing controls",
abstract = "Background/aims We wished to determine whether the pupillary light reaction can differentiate preclinical Alzheimer's disease (AD) subjects from normal ageing controls. We performed a prospective study evaluating the pupillary light reaction in a cohort of well-characterised subjects with preclinical AD versus normal ageing controls. Methods We recruited 57 subjects from our institution's Memory and Aging Project, part of our Alzheimer's Disease Research Center. All subjects completed PET-PiB imaging, cerebrospinal fluid analysis and at least 1 neuropsychiatric assessment after their baseline assessment. All participants were assigned a clinical dementia rating and underwent a complete neuro-ophthalmic examination. Participants were divided into a dementia biomarker+ (preclinical AD) and biomarker- (normal ageing) group based on preclinical risk for Alzheimer's dementia. Pupillometry measurements were performed by using the NeurOptics PLR-200 Pupillometer. Results A total of 57 subjects were recruited with 24 dementia biomarker+ and 33 dementia biomarker- individuals. A variety of pupil flash response (PLR) parameters were assessed. Comparisons between groups were analysed using generalised estimating equations. None of the pupillary parameters showed a significant difference between groups. Conclusions We found no significant differences in PLR between preclinical AD subjects and normal ageing controls. This suggests that the disease effect on the PLR may be small and difficult to detect at the earliest stages of the disease. Future studies could include larger sample size and chromatic pupillometry.",
keywords = "physiology, pupil",
author = "{Van Stavern}, {Gregory P.} and Ling Bei and Shui, {Ying Bo} and Julie Huecker and Mae Gordon",
note = "Funding Information: This study was approved by the institutional review board at Washington University in Saint Louis School of Medicine and the University's Human Research Protection Office. Participants provided informed consent. Participants were recruited from the Memory and Ageing Project of the Knight Alzheimer Disease Research Center (ADRC) of the Department of Neurology of Washington University. All participants were research volunteers and undergo yearly neurological examination, including neuropsychometric testing and also undergo yearly amyloid beta PET imaging and/or CSF amyloid beta measurements. They are assigned a clinical dementia rating (CDR) at each yearly visit, based on the combined results of these tests. A CDR of 0 indicates no evidence of cognitive dysfunction or AD. All participants in the ADRC are offered the opportunity to participate in a wide variety of clinical research projects. All subjects in our study were contacted by ADRC staff members and asked if they wished to participate in our study. Those who agreed were then contacted by our research coordinators to set up a time for the research visit. Funding Information: Funding This study was funded by Research to Prevent Blindness (Grant Number: P30 EY02687). This study was supported by the Knight Alzheimer{\textquoteright}s Disease Research Center, and the following grants: P50 AG05681; PO1 AG03991; PO1 AG026276. Funding Information: Acknowledgements Research was supported by DOVS Core Grant 5 P30 EY02687, Institute for Clinical and Translational Sciences grant RR023496, Biostat Core Grant U54 RR023496, an unrestricted grant from Research to Prevent Blindness, and NIH Core Vision Grant P30 EY02687. Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2019",
month = jul,
day = "1",
doi = "10.1136/bjophthalmol-2018-312425",
language = "English",
volume = "103",
pages = "971--975",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
number = "7",
}